Here we demonstrate that these individuals does not have increased breast and ovarian cancer risk, because the frequency of FANCG pathogenic variants among cancer patients are not different from that in controls, the tumors in FANCG carriers showed no loss‐of‐heterozygozity of wild type allele, and functional in vitro analysis found that any tested rare missense variant impaired FANCG capacity in DNA repair. This evidence concerns the gene FANCG and ovarian cancer.